Department of Gynecology and Obstetrics, Charité University Hospital, Campus Virchow-Clinic, Berlin, Germany.
Int J Gynecol Cancer. 2009 Dec;19(9):1550-5. doi: 10.1111/IGC.0b013e3181a84699.
Borderline ovarian tumors (BOTs) are rare entities with excellent prognosis depending on tumor stage and presence of invasive implants. There are limited data regarding the intraoperative tumor pattern, the actual base of optimal treatment planning. We conducted a systematic evaluation of the macroscopic and microscopic tumor spreads in patients with BOTs with special focus on the diagnosis of invasive and noninvasive lesions.
Between January 2001 and July 2008, data of patients with BOTs were evaluated using a systematic and validated documentation tool (intraoperative mapping of ovarian cancer). Surgical outcome and pathological findings were analyzed.
Fifty-one patients underwent surgery for BOT. Mean (SD) age was 47.76 (15.9) years. In 6 patients (11.8%), surgery was performed for recurrence. Complete tumor resection was achieved in 47 patients (92.15%), whereas mean (SD) operative time was 126.34 (73.4) minutes. Pathologic evaluation identified 12 patients (23.53%) with mucinous and 39 patients (76.47%) with serous histologic diagnoses. Twenty-nine (56.86%) and 22 patients (43.13%) were found to have unilateral and bilateral ovarian involvements, respectively. Sixteen patients (31.37%) presented extraovarian involvement into the peritoneum (23.5%), omentum (17.7%), uterus (7.84%), sigmoid (7.8%), lymph nodes (7.8%), ileum (3.9%), mesentery (5.9%), and appendix (1.96%). Twenty patients (39.2%) had implants; of those, 9 (17.64%) and 11 patients (21.6%) have invasive and noninvasive lesions, respectively. Eight of the 9 patients with positive peritoneal cytology were associated with the presence of peritoneal implants; 3 of them with invasive character.
Borderline ovarian tumors require a systematic surgical evaluation to verify or exclude extrapelvic tumor lesions and allow further clinical relevant differentiation between invasive and noninvasive implants.
交界性卵巢肿瘤（BOT）是一种罕见的实体肿瘤，其预后取决于肿瘤分期和是否存在侵袭性种植。目前关于术中肿瘤模式的数据有限，而肿瘤模式是优化治疗计划的实际基础。我们对患有 BOT 的患者进行了一项系统性评估，特别关注侵袭性和非侵袭性病变的诊断。
2001 年 1 月至 2008 年 7 月，我们使用系统的和经过验证的记录工具（卵巢癌术中绘图）评估了患有 BOT 的患者的数据。分析了手术结果和病理发现。
51 例患者因 BOT 接受了手术。患者的平均（SD）年龄为 47.76（15.9）岁。在 6 例患者（11.8%）中，手术是为了治疗复发。47 例患者（92.15%）实现了完全肿瘤切除，而平均（SD）手术时间为 126.34（73.4）分钟。病理评估显示，12 例（23.53%）为黏液性，39 例（76.47%）为浆液性组织学诊断。29 例（56.86%）和 22 例（43.13%）患者单侧和双侧卵巢受累，分别。16 例（31.37%）患者出现卵巢外累及腹膜（23.5%）、大网膜（17.7%）、子宫（7.84%）、乙状结肠（7.8%）、淋巴结（7.8%）、回肠（3.9%）、肠系膜（5.9%）和阑尾（1.96%）。20 例（39.2%）患者有种植物；其中，9 例（17.64%）和 11 例（21.6%）患者分别有侵袭性和非侵袭性病变。9 例腹膜细胞学阳性患者中，8 例与腹膜种植物有关，其中 3 例具有侵袭性特征。
交界性卵巢肿瘤需要进行系统的手术评估，以验证或排除盆腔外肿瘤病变，并进一步对侵袭性和非侵袭性种植物进行有临床意义的区分。
